BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated protein 1 Paul Bonanos Vivace Therapeutics Inc. MinervaX ApS Arvinas Inc. BioAtla Inc. Neurogene Inc. Atsena...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Ron Carter as CMO. Weinberg was CMO of 4D Pharma plc (LSE:DDDD). Neurological diseases company Neurogene Inc....
...Pharma S.A. Kiadis Pharma N.V. Tarsus Pharmaceuticals Inc. MaaT Pharma S.A. Poseida Therapeutics Inc. AnaptysBio Inc. Scholar Rock Holding Corp. Zikani Therapeutics Inc. Neurogene Inc....
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...the Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Noven Pharmaceuticals Inc. Hisamitsu Pharmaceutical Co. Inc. Illumina Inc. Precision Biologics Inc. CureDuchenne Neurogene Inc. Artios...
BioCentury | Apr 4, 2019
Translation in Brief

Promoting AAV vectors to safety

...AAV-based gene therapies. Among the newest players in the field are Passage Bio Inc. and Neurogene Inc....
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

...viral (AAV)-based gene therapy to deliver AGA could help treat the lysosomal storage disorder aspartylglucosaminuria Neurogene Inc....
...suggest an AAV-based gene therapy to deliver FIG4 could help treat Charcot-Marie-Tooth disease type 4J Neurogene Inc....
BioCentury | Mar 15, 2019
Emerging Company Profile

Neurogene: Genes over ERT for monogenic CNS diseases

...BBB), and there have been no attempts to develop a therapy for CMT4J. She said Neurogene Inc....
...indications outside of gene therapy, and to establish a viral vector manufacturing facility. COMPANY PROFILE Neurogene Inc....
...and an undisclosed healthcare investment fund CEO: Rachel McMinn Patents: Undisclosed Companies and Institutions Mentioned Neurogene Inc....
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

...see “Passage Bio Debuts with $115.5M for CNS Gene Therapies” ). Fellow gene therapy company Neurogene Inc....
...TMEM173) - Transmembrane protein 173 BC Staff Arvelle Therapeutics GmbH Culture Biosciences Inc. Grey Wolf Therapeutics IFM Therapeutics LLC Indalo Therapeutics Inc. Neurogene Inc. NodThera...
BioCentury | Feb 15, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

...senior biotechnology analyst at BofA Merrill Lynch, Cowen and Piper Jaffray. Neurogene Inc., New York, N.Y. Chris Lieu Neurogene Inc....
BioCentury | Feb 12, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

...Inc. (NASDAQ:ICPT) and a senior biotechnology analyst at BofA Merrill Lynch, Cowen and Piper Jaffray. Chris Lieu Neurogene Inc....
BioCentury | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

...a director. Finney was COO at Zavante Therapeutics Inc., which Nabriva Therapeutics plc (NASDAQ:NBRV) acquired. Neurogene Inc....
Items per page:
1 - 10 of 10
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated protein 1 Paul Bonanos Vivace Therapeutics Inc. MinervaX ApS Arvinas Inc. BioAtla Inc. Neurogene Inc. Atsena...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Ron Carter as CMO. Weinberg was CMO of 4D Pharma plc (LSE:DDDD). Neurological diseases company Neurogene Inc....
...Pharma S.A. Kiadis Pharma N.V. Tarsus Pharmaceuticals Inc. MaaT Pharma S.A. Poseida Therapeutics Inc. AnaptysBio Inc. Scholar Rock Holding Corp. Zikani Therapeutics Inc. Neurogene Inc....
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...the Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Noven Pharmaceuticals Inc. Hisamitsu Pharmaceutical Co. Inc. Illumina Inc. Precision Biologics Inc. CureDuchenne Neurogene Inc. Artios...
BioCentury | Apr 4, 2019
Translation in Brief

Promoting AAV vectors to safety

...AAV-based gene therapies. Among the newest players in the field are Passage Bio Inc. and Neurogene Inc....
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

...viral (AAV)-based gene therapy to deliver AGA could help treat the lysosomal storage disorder aspartylglucosaminuria Neurogene Inc....
...suggest an AAV-based gene therapy to deliver FIG4 could help treat Charcot-Marie-Tooth disease type 4J Neurogene Inc....
BioCentury | Mar 15, 2019
Emerging Company Profile

Neurogene: Genes over ERT for monogenic CNS diseases

...BBB), and there have been no attempts to develop a therapy for CMT4J. She said Neurogene Inc....
...indications outside of gene therapy, and to establish a viral vector manufacturing facility. COMPANY PROFILE Neurogene Inc....
...and an undisclosed healthcare investment fund CEO: Rachel McMinn Patents: Undisclosed Companies and Institutions Mentioned Neurogene Inc....
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

...see “Passage Bio Debuts with $115.5M for CNS Gene Therapies” ). Fellow gene therapy company Neurogene Inc....
...TMEM173) - Transmembrane protein 173 BC Staff Arvelle Therapeutics GmbH Culture Biosciences Inc. Grey Wolf Therapeutics IFM Therapeutics LLC Indalo Therapeutics Inc. Neurogene Inc. NodThera...
BioCentury | Feb 15, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

...senior biotechnology analyst at BofA Merrill Lynch, Cowen and Piper Jaffray. Neurogene Inc., New York, N.Y. Chris Lieu Neurogene Inc....
BioCentury | Feb 12, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

...Inc. (NASDAQ:ICPT) and a senior biotechnology analyst at BofA Merrill Lynch, Cowen and Piper Jaffray. Chris Lieu Neurogene Inc....
BioCentury | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

...a director. Finney was COO at Zavante Therapeutics Inc., which Nabriva Therapeutics plc (NASDAQ:NBRV) acquired. Neurogene Inc....
Items per page:
1 - 10 of 10